Timing, Fundamentals, and Diversification of Concert Pharmaceuticals Inc. (CNCE)

The closing price of Concert Pharmaceuticals Inc. (NASDAQ: CNCE) was $5.16 for the day, up 0.39% from the previous closing price of $5.14. In other words, the price has increased by $+0.02 from its previous closing price. On the day, 273905 shares were traded. CNCE stock price reached its highest trading level at $5.30 during the session, while it also had its lowest trading level at $5.11.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.



Our analysis of CNCE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 9.00 and its Current Ratio is at 9.00. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Berenberg on December 16, 2020, initiated with a Buy rating and assigned the stock a target price of $25.

On March 30, 2020, Jefferies started tracking the stock assigning a Buy rating and target price of $23.

H.C. Wainwright reiterated its Buy rating for the stock on October 03, 2019, while the target price for the stock was revised from $29 to $25.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 14 when HUTT PETER BARTON sold 3,539 shares for $6.09 per share. The transaction valued at 21,553 led to the insider holds 29,488 shares of the business.

van Heek Christi bought 10,526 shares of CNCE for $49,998 on Jun 06. The Director now owns 25,651 shares after completing the transaction at $4.75 per share. On Jun 06, another insider, Auchincloss Thomas G, who serves as the Director of the company, bought 6,000 shares for $4.75 each. As a result, the insider paid 28,500 and bolstered with 17,625 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 7.53 while its Price-to-Book (P/B) ratio in mrq is 1.93.

Stock Price History:

Over the past 52 weeks, CNCE has reached a high of $7.37, while it has fallen to a 52-week low of $2.57. The 50-Day Moving Average of the stock is 5.78, while the 200-Day Moving Average is calculated to be 4.79.

Shares Statistics:

CNCE traded an average of 478.37K shares per day over the past three months and 303.57k shares per day over the past ten days. A total of 49.73M shares are outstanding, with a floating share count of 43.92M. Insiders hold about 1.10% of the company’s shares, while institutions hold 72.50% stake in the company. Shares short for CNCE as of Oct 13, 2022 were 1.88M with a Short Ratio of 2.12M, compared to 1.24M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 3.92% and a Short% of Float of 4.24%.

Earnings Estimates

The firm’s stock currently is rated by 5 analysts. On average, analysts expect EPS of -$0.59 for the current quarter, with a high estimate of -$0.52 and a low estimate of -$0.64, while EPS last year was -$0.78. The consensus estimate for the next quarter is -$0.59, with high estimates of -$0.52 and low estimates of -$0.68.

Analysts are recommending an EPS of between -$2.56 and -$2.9 for the fiscal current year, implying an average EPS of -$2.76. EPS for the following year is -$2.04, with 5 analysts recommending between -$1.45 and -$2.86.